Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62222 | 1.00 | TSHR (0.32) | TSHRCYP2C19 | |
| SCHEMBL61654 | 1.00 | TSHR (0.32) | TSHRCYP2C19 | |
| Hydrochloric Acid SCHEMBL9009933 | 0.97 | TSHR (0.31) | TSHRCYP2C19 | |
| SCHEMBL61974 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3168559 | 0.95 | — | — | |
| SCHEMBL61735 | 0.92 | — | — | |
| SCHEMBL61083 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL8681308 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL5960763 | 0.81 | — | — | |
| SCHEMBL4441457 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1794 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122239-A1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2025-04-17 | — | — | US | claimed |
| CN-119119207-A | Phase separated polypeptide and GLP-1 RAs derivative containing same | 北京化工大学 | 2024-12-13 | — | — | CN | claimed |
| CN-118994411-A | High-stability long-acting GLP-1 RAs derivative | 北京化工大学 | 2024-11-22 | — | — | CN | claimed |
| EP-3891176-B1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2024-06-05 | — | — | EP | claimed |
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| EP-3250191-B1 | TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING | NOVO NORDISK AS (DK) | 2024-01-17 | — | — | EP | claimed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| US-20220056077-A1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | RATNER, Cecilia (DK) | 2022-02-24 | — | — | US | claimed |
| CN-107205948-B | Tablets comprising a GLP-1 agonist and an enteric coating | 诺和诺德股份有限公司 | 2021-12-14 | — | — | CN | claimed |
| EP-3891176-A1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | Københavns Universitet (DK) | 2021-10-13 | — | — | EP | claimed |
| WO-2005058954-A1 | NOVEL GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| WO-2005058958-A2 | NOVEL GLP-1 ANALOGUES LINKED TO ALBUMIN-LIKE AGENTS | NOVO NORDISK A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| WO-2005028516-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2005-03-31 | — | — | WO | claimed |
| WO-2005027978-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2005-03-31 | — | — | WO | claimed |
| US-20040048788-A1 | Sh2 domain binding inhibitors | DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, OF THE | 2004-03-11 | — | — | US | claimed |
| EP-1383792-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2004003005-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-01-08 | — | — | WO | claimed |
| WO-2002016407-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-02-28 | — | — | WO | claimed |
| EP-1163262-A1 | PHENYLALANINE DERIVATIVES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2000056760-A1 | PHENYLALANINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-09-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048788-A1 | Sh2 domain binding inhibitors | ACP1, PHLPP1, SORBS1 | TSHR 1243/4885CYP2C19 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.